SimInhale COST Action MP1404

SimInhale COST Action MP1404

Simulation and pharmaceutical technologies for advanced patient-tailored inhaled medicines

Program at a glance

Funding AgenciesEuropean Commission (COST Organisation)
Program Period2014-2017 
Action AcronymSimInhale 
Action NameSimulation and pharmaceutical technologies for advanced patient-tailored inhaled medicines 
Chair of the ActionDr. Stavros Kassinos 
COST Website 
Dedicated Webpage 

Program Overview

As a result of the culmination of several scientific and technological developments, we were on the verge of technological breakthroughs in the field of inhaled medicines that will revolutionize the treatment of many acute or chronic respiratory and systemic illnesses. However, knowledge in the field is vertically fragmented and compartmentalized in disciplines. As a result, current developments are not necessarily synergistic and supportive of each other. The prospect of patient-tailored inhaled medicines necessitates a much closer coordination of research and development activities.Simlnhale aimed at creating a pan-European network of experts in order to: i) advance particle designs for improved deposition and interaction with lung tissue, ii) promote realistic computer simulations of particle aerosolization, delivery and deposition, iii) promote patient-tailored inhaled medicines, iv) promote integration of device and formulation design, and v) promote critical assessment of toxicity issues and related risks. Making a new generation of advanced inhaled pharmaceuticals available to patients in a shorter period of time had significant social benefits. It also have significant economic benefits, since it will advance pharmaceuticals with higher effectiveness and fewer side effects, thus reducing health care costs in the long run, and will help sustain innovation in the industry of inhaled pharmaceuticals and inhaler devices.

Working Groups

WG1: Particle engineering/processing of inhaled medicines for local/systemic action

WG2: Device engineering and formulation-aware inhaler design

WG3: Computer simulations as a horizontal enabling technology: delivery, deposition and lung-tissue/particles interaction

WG4: Advanced imaging, patient monitoring and delivery verification

WG5: Toxicity, xenobiotics, risk assessment and policy development

Scroll to Top